CXCR3 and hepatocellular carcinoma: Chuah et al. [93] identified the interaction between CXCR3+ effector memory CD8+ T cells and HLA-DR+ APCs as a key mechanism determining response versus irAEs in patients with HCC treated with anti-PD-1 ICI.